Organ-on-Chip Market Expected to Reach $1.6 Billion by 2030—Allied Market Research

The global organ-on-chip market was valued at $103.44 million in 2020, and is estimated to reach $1.6 billion by 2030, growing at a CAGR of 31.1% from 2021 to 2030. An organ-on-a-chip (OOC) is a microfluidic cell culture device developed using microchip manufacturing methods that contains continuously perfused chambers inhabited by living cells arranged to simulate tissue- and organ-level physiology. This chip develops a narrow channel for the blood and air flow in organs including lung, gut, liver, and heart. Such devices produce multiple levels of tissue and organ functionality, which is not possible using conventional 2D and 3D culture systems. Organ-on-chip offers a wide range of applications such as diseases modelling, patient stratification, and phenotypic screening.

Growth of the organ-on-chip market is majorly driven by rise in drug discovery, increase in organ failures, surge in need for organ transplantations, and rise in strategic developments among key players of the market. The global organ-on-chip market benefit from an increase in demand for organ-on-chip devices in the healthcare industry. Organ-on-chip technologies are used in the healthcare industry for real-time imaging and in-vitro analysis of biochemical, genetic, and metabolic activities of living cells in a functional tissue.

Increase in disease load, significantly rise in patient pool, and requirement for personalized treatments have surged the demand for organ-on-chip in drug screening. Drug screening is a cost-effective way for evaluating samples quickly. Organ-on-chip culture systems are used by scientists and researchers to track the effects of drugs in the body. In addition, this approach is used to check drug toxicity or effectiveness in various organs of the body.

Furthermore, in December 2020, Emulate, Inc., a leading provider of innovative in vitro models in the organ-on-chip industry, announced the launch of Emulate Brain-chip, which is intended for neuroinflammatory disease researchers and for  drug developers looking to accelerate drug development for neurodegenerative diseases, including Alzheimer's and Parkinson's. Thus, such product launch, collaborations, and partnerships among key players are expected to  drive the market growth.

However, high development & manufacturing cost and the technology being in the nascent stage and research being conducted to enhance its success rates are expected to impede the market growth. Conversely, high market potential in the developing emerging economies for R&D, rise in various strategies among governments & key players, and development of pipeline products are expected to provide many opportunities for the organ-on-chip market size growth during the forecast period.

Depending on type, the organ-on-chip market analysis lung-on-chip segment generated maximum revenue in 2020, accounting for $21.37 million. The heart-on-chip segment is expected to witness highest CAGR of 32.8% during the forecast period.

Region wise, North America exhibited the global organ-on-chip market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of technologically advanced models, presence of key players, and rise in R&D activities for drug discovery & development. However, Asia-Pacific organ-on-chip market size is anticipated to witness notable growth in theorgan-on-chip industry, owing to increase in R&D activities, increase in healthcare investment, and various strategies among the key players.